Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 20, 2020

View Archived Issues

Nanoparticle fights pancreatic cancer's chemo resistance

FLUVID influenza-COVID-19 therapeutic cocktail demonstrates effective antiviral activity

Lumasiran approved in the E.U. for the treatment of PH1

First patient dosed in phase I study of SEFA-1024

Black Swan Pharmaceuticals patents antisense oligonucleotides targeting SOD1

New CD73 inhibitors discovered at Abbisko Therapeutics

Sotatercept for RV-PA coupling and RV function improvement in PAH

Sichuan Kelun-Biotech Biopharmaceutical identifies new STING agonists

New HBsAg and HBeAg secretion inhibitors discovered at Nanjing Hepo Pharmaceuticals

Jiangsu Carefree Pharmaceutical synthesizes new tyrosine kinase receptors inhibitors

Promore reports phase IIb data on ropocamptide for venous leg ulcers

Promising preclinical data for AK-119 as potential immunotherapy for COVID-19

Investigators plant better AID for protein degradation

Nourin-dependent miR-137 as early diagnostic biomarker for unstable angina

Phase III RATIONALE 303 trial of tislelizumab in NSCLC meets primary endpoint at interim analysis

IL-2-antibody fusion shows promising effects in metastatic melanoma and breast cancer murine models

FDA issues EUA for baricitinib with remdesivir for hospitalized COVID-19 patients

AVO-101: promising results for weight loss and NASH reduction

New trial evaluates F4 Pharma's FX-06 in patients with severe COVID-19

Novel mouse model allows efficacy evaluation of checkpoint inhibitors targeting CD28

Enrollment begins in registrational trial of Nyxol to reverse pharmacologically induced mydriasis

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...